Login / Signup

Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients.

Samantha TamChi-Fang WuHo-Lan PengKristina R DahlstromErich M SturgisDavid R Lairson
Published in: The Laryngoscope (2019)
N/A Laryngoscope, 130:1186-1194, 2020.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • healthcare
  • health insurance